ICR welcomes appointment of Aviva and Socius for new life-sciences development at The London Cancer Hub 22 Jan 2024 The Institute of Cancer Research has welcomed the appointment of a new partnership to deliver a major redevelopment project at The London Cancer Hub in Sutton. Find out more Show/Hide
ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
Stage set for major new life-sciences redevelopment at The London Cancer Hub 04 Oct 2023 The ICR has welcomed the news that insurer Aviva and developer Socius have been announced as the preferred bidder for a major life-sciences redevelopment project at The London Cancer Hub in Sutton. Find out more Show/Hide